Dynorphin fragments, mu/delta ligands, delta ligands and certain nonopioid peptides regulate in vivo morphine-induced and beta-endorphin-induced effects. These data suggest complex interactions between these peptides and mu opioids or beta-endorphin. Thus, many endogenous peptides from diverse peptide families are most likely involved in opioid-related homeostatic processes. We are currently studying the in vivo effects of dynorphin-A-(1-13) on morphine-induced changes in EEG, EEG spectral parameters, and behavior in rats. We are proposing extensions of these ongoing studies with the following specific aims. (1.) Determine whether the antagonism of morphine-induced changes in EEG spectral parameters by dynorphin fragments, mu/delta ligands, delta ligands and certain nonopioid peptides is competitive or non-competitive. (2.) Determine whether the regulatory effects of these peptides are sensitive to reversal by selective antagonists. (3.) Determine whether the regulatory effects of these peptides are affected by the relative state of morphine tolerance. (4.) Determine whether the enhancing effects of the mu/delta peptide leucine enkephalin and the delta peptide DPDPE are sensitive to reversal by a selective delta antagonist. (5.) Determine whether the enhancing effects of these peptides are affected by the relative state of morphine tolerance. Assessments of pharmacological similarities and differences among the regulatory effects of these endogenous peptides and related synthetic opioids should contribute to further understanding of the functional roles of these endogenous peptides. Furthermore, extensive studies of the in vivo interactions between various endogenous peptides and structurally related synthetic peptides seem warranted because the acquired information might be beneficial for the clinical management of pain and the clinical treatment of opioid dependence and abuse. Morphine and related mu opioid agonists are extensively used clinically. These in vivo interactions can be effectively delineated in our EEG and EMG rat model in which effects of opioids or cortical EEG and associated behavior have been studied for several years. In the presently proposed studies, EEG spectral parameters will allow assessments and comparisons of quantitative and qualitative, regulatory effects of opioid and nonopioid neuroactive peptides on morphine-induced effects in non-tolerant and morphine-tolerant rats.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA001050-18
Application #
2116411
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1975-10-01
Project End
1993-12-31
Budget Start
1992-01-01
Budget End
1993-12-31
Support Year
18
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Haberny, K A; Young, G A (1995) Acute interactive effects of MK-801 and morphine on cortical EEG and EEG power spectra in rats. Brain Res Bull 36:325-31
Haberny, K A; Young, G A (1994) Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behavior in rats: I. Morphine tolerance development. Eur J Pharmacol 261:1-9
Haberny, K A; Young, G A (1994) Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behavior in rats: II. Morphine dependence. Eur J Pharmacol 261:11-6
Meng, Y; Young, G A (1994) Dynorphin A-(1-13)-morphine interactions: quantitative and qualitative EEG properties differ in morphine-naive vs. morphine-tolerant rats. Brain Res Bull 33:255-65
Young, G A; Hudson, G M; Stamidis, H et al. (1993) Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates. Eur J Pharmacol 231:473-6
Stamidis, H; Young, G A (1993) Mu-delta opioid interactions. III: Differential antagonism of DPDPE-induced increases in morphine EEG and EEG power spectra by DALCE and naltrindole. Peptides 14:511-7
Mayo-Michelson, L; Young, G A (1993) Genetic profiles of morphine-induced EEG, EEG power spectra, and behavior in two inbred rat strains. Brain Res Bull 30:79-84
Stamidis, H; Young, G A (1992) Mu-delta opioid interactions. II: Beta-FNA inhibits DPDPE-induced increases in morphine EEG and EEG spectral power. Peptides 13:755-60
Hudson, G M; Marquis, K L; Stamidis, H et al. (1992) Cholecystokinin octapeptide alters morphine-induced effects on EEG power spectra both quantitatively and qualitatively. Eur J Pharmacol 221:217-22
Stamidis, H; Young, G A (1992) Naltrindole retards tolerance development to morphine-induced effects on EEG and EEG power spectra. Eur J Pharmacol 213:9-16

Showing the most recent 10 out of 22 publications